Business
Investment and Placing of New Shares
Investment and Placing of New Shares.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n\n \nEDX Medical Group plc\nInvestment and Placing of New Shares\nEDX Medical Group plc · EDX\n6 February 2024\nEDX Medical Group plc (\"EDX Medical\" or the \"Company\"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces that the Board of the Company has today approved the issue of 33,425,000 new ordinary shares of 1p each in the Company (\"Ordinary Shares\") at a price of 12p per share (the \"Subscription\", \"Subscription Shares\") to raise £4.01million for the Company. The issue of the new ordinary shares is the initial element of a fundraising round to support the acceleration of the development of new diagnostic products to help meet global demand from healthcare providers delivering personalIsed treatments.\nThe funding round has been led by Professor Sir Chris Evans, OBE, founder of EDX Medical, who has invested £750,000 as a result of subscribing for 6,250,000 of the Subscription Shares at the Subscription Price.\nSeveral existing and new investors including Steve Morgan, CBE, (Bridgemere Securities Ltd), Sir Tony Gallagher (Countywide Developments Ltd), Sir Tom Hunter (West Coast Capital Holdings Ltd), Sir Peter Michael (Stockford Ltd), Lord Lloyd Webber (Lynchwood Nominees), Lord John Nash (LGT Wealth Management), Bill Holroyd (The Holroyd Investment Trust) and David Rees (Seerave Enterprises Ltd) have also subscribed.\nThe Company intends to raise further capital in this round and is in discussions with other shareholders and potential new investors about participation in the Subscription, and consequently, the Subscription will remain open to new and existing shareholders, at the Subscription Price, until February 19th.\nApplication will be made for the Subscription Shares to be admitted to trading on the AQSE Growth Market (\"Admission\") and the Subscription remains conditional on Admission.\nProfessor Sir Chr...